Galileo Research is a non-clinical Contract Research Organization (CRO) that specializes in providing comprehensive research and development services for drugs, medical devices, cosmetics, and food supplements. The organization leverages over 30 years of experience in conducting Good Laboratory Practice (GLP)-compliant studies, focusing on areas such as toxicology, biocompatibility, efficacy, and mechanisms of action. Their expertise extends to drug discovery and development, where they assist pharmaceutical companies in selecting lead candidates and conducting a range of preclinical studies, including toxicological screening, pharmacology, and pharmacokinetics. This approach aims to accelerate the development of new medicines while adhering to international regulatory guidelines.

In addition to drug development, Galileo Research offers specialized services for medical devices, cosmetics, and food safety evaluations. They conduct in vitro testing to ensure product safety and efficacy, as well as GLP-compliant non-clinical toxicity studies to support regulatory submissions. Their capabilities also include biological evaluations for medical devices, where they review existing data and perform necessary tests to guarantee product safety. By employing a variety of experimental methodologies, both in vitro and in vivo, Galileo Research is committed to providing tailored solutions that meet the specific needs of their clients across multiple sectors in the life sciences industry.

Italy

Galileo Research origins lie in 1972 as the Research Centre of Istituto Gentili, an Italian pharmaceutical company founded in 1917. At the beginning of the ‘80s, scientists at the Gentili Research Centre discovered and developed new molecules in the class of bisphosphonates and in the field of bone diseases, in particular clodronate and alendronate. The Research Centre continued to work in the field of bone and joint metabolism and also expanded its knowledge and activities to the areas of oncology and CNS. Galileo Research was established in July 2011.

Galileo Research

Company Details